IGFBP2抗体—艾普蒂

+ +

•  

   

     The image is immunohistochemistry of paraffin-embedded Human liver cancer tissue using P05699(IGFBP2 Antibody) at dilution 1/30. (Original magnification: ×200)    

  
  

The insulin-like growth factor-binding protein 2 (IGFBP2) antibody is a crucial tool for studying the role of IGFBP2. a member of the IGFBP family that modulates the bioavailability and activity of insulin-like growth factors (IGFs). IGFBP2 binds IGF-1 and IGF-2. regulating their interaction with cell surface receptors, thereby influencing cell proliferation, differentiation, and metabolism. Dysregulation of IGFBP2 is implicated in various pathologies, including cancer, metabolic disorders, and neurodegenerative diseases. Elevated IGFBP2 levels are frequently observed in malignancies like glioblastoma, breast, and colorectal cancers, where it promotes tumor progression via IGF-dependent and IGF-independent pathways, such as integrin signaling.

IGFBP2 antibodies are widely used in research to detect and quantify IGFBP2 expression in tissues and biofluids (e.g., serum, cerebrospinal fluid) using techniques like Western blotting, immunohistochemistry (IHC), and ELISA. These antibodies aid in elucidating IGFBP2's role in disease mechanisms, prognostic biomarker potential, and therapeutic targeting. Monoclonal antibodies offer high specificity, while polyclonal antibodies may detect multiple epitopes, enhancing detection sensitivity. Validation via knockout controls or immunoprecipitation is critical to ensure antibody reliability. Additionally, IGFBP2 antibodies are employed in functional studies to block or neutralize IGFBP2 activity, helping dissect its molecular interactions. Their application spans cancer biology, neurology, and endocrinology, underscoring IGFBP2's multifaceted roles in health and disease.